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Molecular Defects in the Motor Adaptor BICD2
Cause Proximal Spinal Muscular Atrophy
with Autosomal-Dominant Inheritance
Kristien Peeters,1,2 Ivan Litvinenko,3 Bob Asselbergh,2,4 Leonardo Almeida-Souza,2,5 Teodora Chamova,6
Thomas Geuens,2,5 Elke Ydens,2,5 Magdalena Zimon,1,2 Joy Irobi,4 Els De Vriendt,1,2 Vicky De Winter,2,5
Tinne Ooms,1,2 Vincent Timmerman,2,5 Ivailo Tournev,6,7,9 and Albena Jordanova1,2,8,9,*
Themost common form of spinalmuscular atrophy (SMA) is a recessive disorder caused by deleterious SMN1mutations in 5q13, whereas
the genetic etiologies of non-5q SMA are very heterogeneous and largely remain to be elucidated. In a Bulgarian family affected by auto-
somal-dominant proximal SMA, we performed genome-wide linkage analysis and whole-exome sequencing and found a heterozygous
de novo c.320C>T (p.Ser107Leu) mutation in bicaudal D homolog 2 (Drosophila) (BICD2). Further analysis of BICD2 in a cohort of 119
individuals with non-5q SMA identified a second de novo BICD2 mutation, c.2321A>G (p.Glu774Gly), in a simplex case. Detailed
clinical and electrophysiological investigations revealed that both families are affected by a very similar disease course, characterized
by early childhood onset, predominant involvement of lower extremities, and very slow disease progression. The amino acid substitu-
tions are located in two interaction domains of BICD2, an adaptor protein linking the dyneinmolecularmotor with its cargo. Our immu-
noprecipitation and localization experiments in HeLa and SH-SY5Y cells and affected individuals’ lymphoblasts demonstrated that
p.Ser107Leu causes increased dynein binding and thus leads to accumulation of BICD2 at the microtubule-organizing complex and
Golgi fragmentation. In addition, the altered protein had a reduced colocalization with RAB6A, a regulator of vesicle trafficking between
the Golgi and the endoplasmic reticulum. The interaction between p.Glu744Gly altered BICD2 and RAB6Awas impaired, which also led
to their reduced colocalization. Our study identifies BICD2mutations as a cause of non-5q linked SMA and highlights the importance of
dynein-mediated motility in motor neuron function in humans.Inherited spinal muscular atrophies (SMAs) form a diverse
group of disorders characterized by muscle weakness and
atrophy caused by the degeneration of anterior horn
cells.1,2 Although the most common form of SMA is an
autosomal-recessive condition associatedwith loss-of-func-
tion mutations in SMN1 (MIM 600354) in chromosomal
region 5q13,3 rare families with dominant inheritance
have been reported.4–8 The non-5q SMAs are genetically
and clinically heterogeneous disorders classified by their
pattern of inheritance and distribution of weakness (distal
or proximal).8 The forms with predominantly distal weak-
ness have a clinical overlapwith the distal hereditarymotor
neuropathies,3,9–15 whereas the proximal forms are caused
by mutations in VAPB (MIM 605704),5 LMNA (MIM
150330),16 and TRPV4 (MIM 605427)6 or are linked to
unresolved loci.4,7,17 Furthermore, several clinical entities
remain without a molecular genetic diagnosis.8
We studied a four-generation Bulgarian family (with
Turkish ethnic background) afflicted with autosomal-
dominant proximal SMA (Figure 1A). Disease status in
the affected individuals was determined by clinical exami-
nation and electrophysiological evaluation. All clinical
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The AmThe onset age varied between 1 and 6 years (mean
3.175 1.70 years), and individuals presented with delayed
motor milestones, such as walking (in persons 177.III.1,
177.IV.3, and 177.IV.4), difficulties in getting upright
from a squatting position (Gowers’ sign) and in climbing
stairs, a waddling gait, and slow running. The leg weakness
did not progress significantly over time, given that affected
individuals still remained ambulatory even into the fifth
decade.
Upon neurologic examination, muscle weakness was
limited to the lower extremities and showed predominant
involvement in the proximal leg muscles (Figures 1B and
1C). Distal muscle weakness in the legs (score 4/5 on the
Medical Research Council [MRC] scale for muscle strength)
was found in one of the oldest family members (177.III.1).
Axial muscle involvement, with difficulties in getting up
from a lying position, was present upon disease progres-
sion. Bulbar muscles were spared in all affected individuals.
Other muscles, including those of the face and upper
extremities, showed normal strength. Patellar tendon
reflexes were depressed in nine persons, whereas Achilles
hyporeflexia or areflexia was found in all of them. Reflexes
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Figure 1. Pedigrees, Clinical Features, and Electropherograms of Individuals with BICD2 Mutations
(A and D) Pedigree structure and haplotype analysis of families 177 (A) and 584 (D). The probands are denoted by an arrow. Squares
and circles symbolize males and females, respectively, and symbols with diagonal black lines represent deceased individuals.
Filled symbols denote family members affected by SMA, and open symbols indicate unaffected individuals. Individuals with an
asterisk were selected for exome sequencing. The disease-segregating haplotype on chromosome 9q is indicated in black. Short-tan-
dem-repeat (STR) markers are shown in order from p-ter (top) to q-ter (bottom). Markers of the genome-wide linkage panel are repre-
sented in bold.
(B and C) The clinical features of person 177.III.1 show hypotrophy of proximal and distal muscles of the lower limbs (B) and scapular
winging (C).
(E) The electropherograms of heterozygous BICD2 mutations c.320C>T (p.Ser107Leu) and c.2321A>G (p.Glu774Gly).observed in the proximal muscles of the upper limbs in
person 177.III.1. Skeletal deformities (lumbal hyperlordo-
sis and scapular winging) were present in most affected in-
dividuals. Symmetric wasting was most prominent in the
hip muscles, whereas distal leg muscles seemed atrophic
in the older family members. Sensation was normal for
all modalities. Serum creatine phosphokinase (CPK) levels
were mostly normal.956 The American Journal of Human Genetics 92, 955–964, June 6, 2We performed electromyography (EMG) studies while
maintaining skin temperature over the first dorsal inteross-
eousmuscle at>30.5C on a Toennies NeuroScreen System
(Jaeger GnbH). Sensory and motor nerve conduction
studies showed normal conduction velocities and ampli-
tudes for the upper and lower extremities (Figures S1A
and S1B, available online). EMG showed predominantly
large-amplitude and long-duration motor unit potentials013
Table 1. Clinical and Electrophysiological Features of the Individuals with BICD2 Mutations
Affected Individual
177.II.4 177.III.1 177.III.4 177.III.5 177.III.6 177.III.8 177.IV.3 177.IV.4 177.IV.5 177.IV.6 177.IV.7 584.II.3
Age of onset
(years)
2 2 5 6 4 4 1 1 5 2 4 2
Age at assessment
(years)
48 44 30 24 24 29 6 5 6 3 5 42
Waddling gait þ þ þ þ þ þ þ þ þ þ þ þ
CPK level ND 1,110 178 ND ND ND 120 51 123 ND ND ND
Fasciculations  þ          þ
Muscle Weakness (MRC Scale)
Proximal muscles
in LLs
4 4 4 4 4 4 4 4 4 þ 4 3
Distal muscles
in LLs
5 4 5 5 5 5 5 5 5  5 4
Axial muscles 4 4 5 5 5 5 5 5 5  5 3
Reflexes
Patellar  þ/ þ/ þ þ/ þ/ þ/ þ/ þ/ ND þ/ 
Achilles    þ/ þ/ þ/ þ/ þ/ þ/ ND þ/ 
Deformities and Posture
Scapular winging þ þ  þ þ þ þ þ þ þ þ þ
Lumbal
hyperlordosis
 þ  þ þ  þ þ þ þ þ þ
Hypotrophies
Proximal muscles
in LLs
þ þ  þ þ þ þ  þ   þ
Distal muscles
in LLs
 þ  þ þ  þ     þ
Nerve Conduction Studies and EMG
MCV of the
nervous peroneus
ND 43.5 ND ND ND ND 54.8 58.3 55.1 ND ND 45.0
Anterior horn
involvement
ND þ þ ND ND ND þ þ þ ND ND þ
Normal CPK range: 20–200. The following abbreviations are used: , absent; þ, present; þ/, moderately reduced; MRC, Medical Research Council; LL, lower
limb; CPK, creatine phosphokinase; EMG, electromyography; MCV, motor conduction velocity; and ND, not determined.in the muscles of the lower and upper extremities, in keep-
ing with anterior horn cell damage (Figures S1C and S1D).
All study participants or their legal representatives pro-
vided written informed consent prior to enrollment. Local
institutional review boards approved this study. Genomic
DNAwas isolated from peripheral blood according to stan-
dard procedures.
We performed genome-wide multipoint parametric link-
age analysis on family 177 with Allegro v.1.2c in the easy-
Linkage software18 by using an in-house-developed panel
of 436 polymorphic short-tandem-repeat (STR) markers
under an autosomal-dominant model, equal male and
female recombination rates and allele frequencies, and a
0.0001 disease frequency. Because the disease was pre-
sumed to have originated de novo in the proband, theThe Amdisease status of her unaffected siblings and parents was
put as ‘‘unknown.’’ The initial analysis showed only one
suggestive linkage peak with a LOD R 2.00 on chromo-
some 9q (LOD ¼ 2.71) (Figure S2A). After fine mapping
with additional STR markers, the disease-segregating locus
could be delineated to a 12.7 Mb region containing 132
distinct genes between D9S1812 and D9S176 (Figure 1A
and Figure S2B).
The TargetSeq Exome Enrichment System was used for
library preparation, capture, and enrichment of about
45.1 Mb of coding regions from two affected brothers
(177.IV.5 and 177.IV.6). Fragment reads (75 þ 35 bp)
were sequenced on a SOLiD 5500xl instrument. Mapping
to the human reference genome (GRCh37) and variant
calling were performed with the CLC Genomicserican Journal of Human Genetics 92, 955–964, June 6, 2013 957
Workbench. Subsequent annotation and filtering were
executed with GenomeComb.19
We extracted heterozygous, novel variants (defined as a
frequency % 1% in public databases such as dbSNP137
and 1000 Genomes Project and our in-house collection
of genomes) that were shared between both affected sib-
lings, were located within the linkage interval, and had
an impact on the protein level (nonsynonymous varia-
tions and splice-site changes). The analysis revealed that
the linkage region contained 50 shared variations, of
which only one nonsynonymous variant was novel:
c.320C>T (p.Ser107Leu) in bicaudal D homolog 2
(Drosophila) (BICD2 [MIM 609797; RefSeq accession num-
ber NM_015250.3]). This missense mutation cosegregated
with disease in the family, as shown by bidirectional
sequencing with the BigDye Terminator v.3.1 Cycle
Sequencing kit on an ABI3730xl DNA Analyzer (Applied
Biosystems), and was, as presumed, a de novo event in
the disease founder, 177.II.4 (Figures 1A and 1E). It was
absent in a cohort of 289 ancestry-matched controls
(51 Bulgarian Turks, 51 Bulgarians, and 187 Turks). Inter-
estingly, the c.320C>T BICD2 mutation is positioned
within a CpG dinucleotide. Given that an estimated 80%
of CpG cytosines are methylated in human cells,20 the
c.320 position could as such be a potential mutational
‘‘hotspot,’’ prone to C>T transitions through spontaneous
deamination of 5-methylcytosine.21,22
In order to obtain further genetic evidence of BICD2-
dependent pathogenicity, we performed an unbiased
screen of all coding exons and exon-intron boundaries of
BICD2 (primers are available upon request) in a cohort of
119 unrelated Bulgarian simplex cases who presented
with clinical and EMG features of progressive anterior
horn involvement and who had been excluded for SMN1
deletions. In 113 (95%) individuals, the clinical picture
was dominated by proximal muscle weakness, whereas in
6 (5%) persons, distal muscles were mostly affected. The
subjects with proximal SMA were further classified as
having type 1 (27.4%), type 2 (14.1%), type 3 (55.8%), or
type 4 (2.7%). In this cohort, we identified a second het-
erozygous missense mutation in BICD2, c.2321A>G
(p.Glu774Gly), in a Bulgarian simplex case diagnosed
with proximal SMA (Figures 1D and 1E). Haplotype ana-
lysis suggested that this mutation also originated de
novo in the proband (584.II.3) (Figure 1D). The variant
was absent in 304 control individuals (108 Bulgarians,
49 Bulgarian Turks, and 147 Turks). In silico prediction
of the functional effect of both mutations with
PolyPhen-223 and MutationTaster24 showed that they
target highly conserved nucleotide and amino acid resi-
dues and are therefore very likely to be deleterious.
The clinical course of person 584.II.3, who harbors
the BICD2 c.2321A>G (p.Glu774Gly) mutation, was
extremely similar to that of individuals with the
c.320C>T (p.Ser107Leu) mutation. This person was
initially diagnosed with the Kugelberg-Welander type of
SMA (MIM 253400). She presented with delayed motor958 The American Journal of Human Genetics 92, 955–964, June 6, 2milestones, a waddling gait, Gowers’ sign, and proximal
upper-limb fasciculations. Neurological examination
showed predominantly proximal muscle weakness (3/5
on the MRC scale) and some distal muscle involvement,
comparable to that of an age-matched affected individual
in family 177 (177.III.1). EMG analysis showed anterior
horn involvement.
BICD2, an evolutionary conserved motor-adaptor pro-
tein, is implicated in dynein-mediated transport as a
molecular linker between the dynein motor and various
cargos.25–28 According to tissue expression databases
(GeneCards), mammalian BICD2 is widely present. We
confirmed this finding via immunoblot analysis of
BICD2 levels in a range of mouse tissues (Figure S3). In
addition, we could demonstrate a high presence of
BICD2 in the spinal cord, the afflicted tissue in SMA.
BICD2 consists of three highly conserved coiled-coil
regions, of which the N-terminal domain binds to the
dynein motor,25 whereas the C-terminal coiled-coil
domain interacts with various cargos, such as RAB6A
(Figure 2A).26 The BICD2 N terminus on its own has very
strong dynein-recruiting activity and can chronically
impair dynein-dynactin function, thus disturbing retro-
grade trafficking and causing cellular abnormalities
such as Golgi fragmentation and neurofilament swell-
ings.25,27,29 Full-length BICD2 does not display such per-
turbing activities, presumably because the C terminus
regulatesmotor-complex binding and inhibits the N termi-
nus in the native state until after cargo loading.25
Interestingly, the targeted residues are positioned in two
different interaction domains of BICD2. Whereas the
p.Ser107Leu substitution lies within the N-terminal
dynein-binding region, the p.Glu774Gly alteration is
located in the C-terminal cargo-loading domain
(Figure 2A). To study the functional effect of these amino
acid substitutions on BICD2 binding properties, we per-
formed coimmunoprecipitation (coIP) and colocalization
studies in cellular models. To this end, BICD2 expression
constructs in pLenti6/V5-DEST or pLenti6/EGFP-DEST
were generated by Gateway cloning with full-length
human BICD2 cDNA from the IMAGE Human cDNA clone
6169195 (Thermo Fischer Scientific). Mutations were
introduced into the human transcript by site-directed
mutagenesis, and stable SH-SY5Y cell lines were created
by lentiviral transduction as described.30
For the immunoprecipitation experiments, human neu-
roblastoma (SH-SY5Y) cells stably expressing wild-type or
altered BICD2 proteins were grown inmodified Eagle’s me-
dium (Invitrogen) under blasticidin selection. Cell lysates
were incubated with Anti-V5 Agarose (Sigma-Aldrich) or
Protein G Sepharose 4 Fast Flow beads (GE Healthcare)
with monoclonal mouse dynein intermediate chain 1
(DIC) antibody (Abcam) or polyclonal rabbit RAB6 anti-
body (Cell Signaling) according to standard procedures.
We detected enhanced coprecipitation of the
p.Ser107Leu altered protein, compared to wild-type
BICD2, by endogenous DIC pulldown. In a reciprocal013
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C
D
Figure 2. Coimmunoprecipitation of BICD2 and Its Interactors Dynein and RAB6A
(A) Schematic representation of the structure of BICD2. The Ser107 residue is positioned in the N-terminal region that interacts with
dynein, whereas the Glu774 amino acid lies within the C-terminal domain that interacts with RAB6A.
(B) Lysates of SH-SY5Y cells stably expressing BICD2-V5 wild-type and altered proteins were used for immunoprecipitation (IP) with
antibodies against dynein intermediate chain 1 (DIC) and V5. The p.Ser107Leu altered BICD2-V5 coprecipitated more with DIC than
did the wild-type protein in reciprocal experiments. TUBB was used for showing equal loading of the lysates.
(C) Lysates of lymphoblasts from members of family 177 were immunoprecipitated with DIC antibody and show an increased BICD2
load in the samples of the three affected individuals compared to the healthy relative (177.III.2). GAPDH was used for showing equal
loading of the lysates.
(D) Immunoprecipitation (IP) of stable SH-SY5Y cell extracts with RAB6A antibody demonstrates that there is less interaction between
RAB6A and p.Glu774Gly altered BICD2-V5 than between RAB6A and the wild-type. The amount of coprecipitated p.Ser107Leu
BICD2-V5 was comparable to that of the wild-type. GAPDH was used for showing equal loading of the lysates.experiment pulling down BICD2-V5, higher amounts of
DIC coprecipitated with p.Ser107Leu BICD2 than with
the wild-type protein (Figure 2B). To explore whether this
altered N-terminal BICD2 interaction is relevant for the
pathophysiology in humans, we further analyzed lympho-
blast cultures derived from affected individuals with the
same p.Ser107Leu substitution. Consistent with our find-
ings in the BICD2 cellular model, coIP of BICD2 with
DIC showed their enhanced interaction in protein extracts
of three affected persons compared to a healthy family
member (Figure 2C).
The p.Glu774Gly alteration, on the other hand, is local-
ized in the BICD2 C-terminal domain, known to directly
interact with RAB6A, a regulator of Golgi-ER trafficking.26
Pulldown of endogenous RAB6A protein coimmuno-
precipitated less p.Glu774Gly protein than wild-type
BICD2 (Figure 2D). The interaction efficiency between
p.Ser107Leu altered BICD2 and RAB6A was comparable to
that between the wild-type protein and RAB6A (Figure 2D).
To investigate whether these alterations in binding
capacity affect the subcellular localization of BICD2, weThe Amperformed immunocytochemistry experiments in neu-
ronal (SH-SY5Y) and nonneuronal (HeLa) cell lines. HeLa
cells were first transiently transfected with EGFP-tagged
wild-type or altered BICD2 constructs with the use
of Lipofectamine LTX reagent (Life Technologies).
Immunostaining was performed with various antibodies
(see below), and cells were imaged with a LSM700 confocal
microscope (Zeiss) with identical acquisition parameters.
In wild-type-expressing HeLa cells, BICD2-EGFP signal
largely overlapped with the RAB6A signal (polyclonal rab-
bit RAB6A antibody, Cell Signaling), as reported before.26
In line with its reduced coIP, the p.Glu774Gly altered
BICD2, compared to the wild-type protein, showed a
decreased colocalization with RAB6A, as illustrated by
line intensity plots and quantification of fluorescence cor-
relation (Figure 3). Intriguingly, the p.Ser107Leu altered
BICD2 also showed significantly reduced colocalization
with RAB6A-positive regions, albeit less pronounced than
the other altered protein. In addition, only cells expressing
p.Ser107Leu showed an intense punctual signal in the peri-
nuclear region (Figure 3, see arrow). Further analysiserican Journal of Human Genetics 92, 955–964, June 6, 2013 959
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Figure 3. Colocalization of BICD2 and RAB6A Is Reduced by the SMA-Causing BICD2 Alterations
HeLa cells expressing BICD2-EGFP (green) were stained for RAB6A (red). p.Glu774Gly altered BICD2-EGFP is decreased in RAB6A-pos-
itive regions. Also, the p.Ser107Leu altered protein shows reduced colocalization with RAB6A, but not to the same extent as
p.Glu774Gly. In addition, the p.Ser107Leu altered BICD2 shows an intense punctual staining in the perinuclear region (arrow). Graphs
and error bars represent the mean and SEM. The Pearson’s correlation coefficient (calculated with the ImageJ Coloc2 plugin) is deter-
mined in 62, 62, and 61 cells expressing wild-type, p.Ser107Leu, and p.Glu774Gly proteins, respectively, from three independent trans-
fection and immunostaining experiments. *p < 0.05, ***p < 0.001. The scale bar represents 5 mm.demonstrated that this signal colocalized with the micro-
tubule-organizing center (MTOC, as visualized with poly-
clonal rabbit g-tubulin, Abcam), to which dynein motor
transport is directed (Figure 4). Interestingly, previous960 The American Journal of Human Genetics 92, 955–964, June 6, 2studies with a truncated BICD2-N protein showed
enhanced targeting of this BICD2 fragment toward the
MTOC.27 This targeting was associated with Golgi frag-
mentation both in vitro and in vivo.25,29 To test whether013
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Figure 4. The p.Ser107Leu Substitution
in the Dynein Binding Domain Induces
BICD2 Accumulation at the MTOC
Compared to wild-type and p.Glu774Gly
altered BICD2-EGFP, p.Ser107Leu altered
BICD2-EGFP (green) shows increased local-
ization at the MTOC (visualized with
g-tubulin, red). The graph and error bars
represent the mean and SEM of mean
EGFP intensity at the MTOC (white bars)
and in the rest of the cell (black bars)
measured in 34, 37, and 17 HeLa cells
expressing wild-type, p.Ser107Leu, and
p.Glu774Gly proteins, respectively. *p <
0.05. The scale bar represents 10 mm. The
following abbreviations is used: NS, not sig-
nificant.p.Ser107Leu also caused this peculiar phenotype, we
stained our stable transgenic SH-SY5Y lines with the Golgi
marker Giantin (polyclonal rabbit Giantin antibody,
Covance). Indeed, cells expressing p.Ser107Leu BICD2
presented with a disrupted Golgi morphology. This pheno-The American Journal of Humatype was not present in the wild-type
or p.Glu774Gly-expressing cells
(Figure 5), despite comparable levels
of both altered proteins (data not
shown).
Our study links genetic defects in
BICD2 with proximal SMA. We identi-
fied two disease-causing alterations
that are located in different interac-
tion domains and that have dif-
ferential effects on BICD2 binding
properties. Nevertheless, the clinical
presentation of SMA is very similar
in both families. The disease, predom-
inantly involving the lower extrem-
ities, was always recognized in early
childhood as a result of delayed motor
milestones or proximal leg weakness.
Although scapular winging was a
typical feature in our affected individ-
uals, strength of the upper extremities
was preserved. Upon disease progres-
sion, mild involvement of distal leg
and axial muscles was found. How-
ever, the clinical histories we obtained
suggest static or very slowly progres-
sive weakness, given that indepen-
dent ambulation was preserved even
in the fifth decade. Nerve conduction
and EMG studies were consistent
with anterior horn loss and normal
motor conduction velocities.
Unlike in other previously de-
scribed families affected by dominant
SMA characterized by early onset andlower-extremity predominance, artrogryposis and severe
contractures were not present in the affected individuals
in our study.31–33 Their phenotype seems mild and is
more similar to the 14q32-linked SMA,7 which only affects
the lower limbs. Although upper-limb weakness isn Genetics 92, 955–964, June 6, 2013 961
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Figure 5. p.Ser107Leu Altered BICD2
Leads to Golgi Fragmentation
SH-SY5Y cells stably expressing BICD2-
EGFP (green) were immunostained with
the Golgi marker Giantin (red). Compared
to wild-type and p.Glu774Gly mutant
cells, cells with p.Ser107Leu altered
BICD2 show a dispersed Golgi apparatus.
In addition, in p.Ser107Leu mutant cells,
a perinuclear accumulation of BICD2 is
apparent (asterisk). Golgi dispersal is repre-
sented as a ratio between the minimal rect-
angle area around the Giantin-positive
structures (segmented in ImageJ by auto-
matic intensity thresholding) and the total
area of the cell. The graph and error bars
represent the mean and SEM of Golgi
dispersal measured in 131, 103, and 104
SH-SY5Y cells expressing wild-type,
p.Ser107Leu, and p.Glu774Gly proteins,
respectively. ***p < 0.001. The scale bar
represents 5 mm. The following abbrevia-
tion is used: NS, not significant.frequently found in autosomal-dominant SMA,16 in our
affected individuals, scapular winging and fasciculations
were the only symptoms of upper-limb involvement.
The BICD2-associated clinical phenotype overlaps with
that of the most common autosomal-recessive 5q-linked
SMA. Although disease onset was early in the affected indi-
viduals in our study, their phenotype is milder in terms of
degree of progression, preservation of strength in the up-
per limbs, and lack of respiratory involvement.1,2 There-
fore, our findings suggest that screening of BICD2 should
be considered in individuals diagnosed with sporadic prox-
imal SMA, for which SMN1 mutations were excluded. In
our cohort, the frequency of the BICD2 mutation approx-
imated 1.7%.
Our functional studies provide evidence that both the
p.Ser107Leu and p.Glu774Gly BICD2 amino acid substitu-
tions affect the binding properties and subcellular localiza-
tion of this motor adaptor. Both alterations consistently
impaired the colocalization of BICD2 with RAB6A, a
known regulator of Golgi-ER trafficking. The reduced co-962 The American Journal of Human Genetics 92, 955–964, June 6, 2013localization of the p.Glu774Gly
altered BICD2 is in accordance with
its compromised binding to RAB6A.
Although the binding capacity of the
p.Ser107Leu altered protein was pre-
served, it also showed decreased co-
localization with RAB6A-positive
structures. This, however, might be
explained by the stronger dynein
binding and targeting to the MTOC.
By its sequestration, BICD2 will be
withdrawn from its cellular destina-
tion, thus impairing RAB6A targeting.
Interestingly, RAB6A might be
implicated in the trafficking of SMN,
the causal protein for the most com-mon form of SMA. The dynamic transport of SMN-con-
taining granules in the neurites of motor-neuron-like cells
was recently demonstrated to be mediated by the COPI
vesicle-protein complex.34,35 Depletion of COPI results in
reduced SMN levels in the neurites and causes growth-
cone defects, mimicking SMN deficiency in neuronal
cells.34 Excitingly, the trafficking of COPI-coated vesicles
is mediated by the BICD2 binding partner RAB6A.36 Taken
together, these findings provide a mechanistic link among
BICD2, RAB6A, and motor neuron survival.
Cells expressing p.Ser107Leu showed Golgi fragmenta-
tion. Because this phenotype was not present in
p.Glu774Gly-expressing cells and this hallmark was not
associated with neuronal degeneration in a mouse model
expressing a truncated BICD2 N terminus,29 the signifi-
cance of this finding is currently undefined.
Our combined genetic and functional findings demon-
strate that BICD2 function is essential for motor neuron
physiology. This study enlarges the genetic heterogeneity
and clinical spectrum of hereditary SMA and has
important implications for future clinical and molecular
diagnostics of this disease.Supplemental Data
Supplemental Data include three figures and can be found with
this article online at http://www.cell.com/AJHG.Acknowledgments
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